# Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions

> **NCT07052396** · — · RECRUITING · sponsor: **Sanofi** · enrollment: 350 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT07052396
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2029-07-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07052396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07052396, "Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07052396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*